National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 679165

Case Details

VAERS ID: 679165 (history)  
Form: Version 1.0  
Age:   
Gender: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-01-24
Entered: 2017-01-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Contusion, Dizziness, Fatigue, Headache, Paralysis, Syncope
SMQs:, Torsade de pointes/QT prolongation (broad), Haemorrhage terms (excl laboratory terms) (narrow), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Accidents and injuries (narrow), Cardiomyopathy (broad), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Vestibular disorders (broad), Hypotonic-hyporesponsive episode (broad), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: DK0095075131612DNK004841

Write-up: Information has been received from the authors in a literature article. Introduction: Vaccination against human papillomavirus (HPV) is offered to girls and women to prevent cervical cancer. Unfortunately, reporting of possible side effects from vaccination has increased in recent years. Therefore, the present study examines women''s experiences of side effects from the HPV vaccine (manufacturer unknown). Methods: In-depth qualitative interviews were conducted with eight HPV-vaccinated women, aged 25-44 years, who experience side effects from the vaccine. The data were analysed using a narrative methodology. Results: The main reasons for being vaccinated against HPV are fear of cancer and trust in general practitioners (GPs). The women reported feeling stigmatised by GPs and doctors and they feel that these professionals did not acknowledge their symptoms, often assuming that they were due to psychological distress. The lack of acceptance from family and friends has led the women to distance themselves from others and lead a more socially isolated life. The women believe that a diagnosis may validate their symptoms and help others accept their condition. Conclusions: The women feel exceedingly physically and mentally confined in their everyday life, which led them to live a more restricted and solitary life. Since other people tend not to acknowledge their symptoms, the women''s illness behaviour is poorly accepted. The women generally distrust healthcare as they have experienced stigmatization from physicians and do not trust the evidence for the safety of the vaccine. This report concerns to a 25 year old single female patient with no children. The patient''s medical history, concurrent conditions and concomitant medications were not reported. On unspecified dates, the patient received the first and second dose of HPV vaccine (manufacturer unknown) for prophylaxis (dose, strength, route of administration and lot number were not reported). On an unspecified date, after the second dose of HPV vaccine (manufacturer unknown) the patient experienced side effects. On an unspecified date in 2013, the patient received the third dose of HPV vaccine (manufacturer unknown) and the side effects were aggravated. At the reporting time, the outcome of the reported event was unknown. The reported considered the event to be related to HPV vaccine (manufacturer unknown). This follow-up information was received via the author of the article on 19-JAN-2017. On an unknown date in 2012, the patient started therapy with GARDASIL for prophylaxis. On an unknown date in 2013, the patient experienced fatigue, headache, dizziness, bruises, fainting and paralysis. The author considered the events to be serious due to "longer or permanent unfitness for work and disability". The treatment administered for the adverse events was reported as paracetamol. The outcome of the events was reported as worsened. Upon internal review, the event Paralysis was determined to be medically significant. This is one of several reports received from the same literature article (MARRS #1612DNK004981, 1612DNK004850, 1612DNK004996, 1612DNK004588, 1612DNK004650, 1612DNK004656 and 1612DNK004576). Additional information is not expected as the reporter has no further information. Events and narrative updated. Sender''s Comments: DK-009507513-1612DNK004576: DK-009507513-1612DNK004656: DK-009507513-1612DNK004588: DK-009507513-612DNK004650: DK-009507513-1612DNK004850: DK-009507513-1612DNK004981: DK-009507513-1612DNK004996.


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=679165


Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166